ABSTRACT
The expression of hormone receptors (estrogen and progesterone) and human epidermal growth factor receptor-2 (HER2) has been used for both therapeutic and prognostic purposes in the management of breast cancer. The presence of a discordant receptor status complicates the approach to treatment in patients with synchronous bilateral breast cancer. We describe the case of a 45-year-old female with synchronous bilateral breast cancer with a triple-negative tumor and a contralateral HER2-positive tumor and discussed the impact of this on the approach to therapeutic management.
ABSTRACT
The lung is a common site for metastatic cancers such as colorectal and breast cancer but an uncommon site for prostate cancer. The treatment modalities for primary and metastatic lung malignancies differ considerably; therefore, it is essential to distinguish between them. Here, we present a patient with solitary metastatic lung cancer with prostate as the primary source, which was initially considered a primary lung nodule considering his risk factors. The patient later developed other lung nodules and successfully underwent resection of these nodules with no bone involvement at the time. Follow-up computed tomography (CT) of the chest revealed two other new lung nodules and pleural effusion, and magnetic resonance imaging (MRI) of the pelvis showed bone involvement. The patient was started on gonadotropin-releasing hormone therapy with subsequent downtrending prostate-specific antigen (PSA). Although uncommon, prostate cancer can metastasize to the lungs; hence, clinicians must always have a high index of suspicion when a patient presents with a lung nodule, especially with a prior history of prostate cancer.
